Welcome to Andes Biotechnologies

The aim of Andes Biotechnologies is to carry out research and development of new anticancer therapies, especially therapies based on the inactivation of novel non-coding mitochondrial RNA targets by means of anti-sense and/or RNAi technology. Andes has a portfolio of 9 patent applications in key pharmaceutical markets around the world, covering the diagnostic and therapeutic use of noncoding mitochondrial RNA oligonucleotides that have the potential to eliminate tumor cells in many cancers selectively without harming normal cells. The company has a management team with extensive experience in drug development and biotechnology research, which has successfully developed, patented and registered products marketed in the U.S. and Europe.

News